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Abstract
Background Many cancer patients use additional herbs or supplements in combination with their anti-cancer therapy. Green 
tea—active ingredient epigallocatechin-3-gallate (EGCG)—is one of the most commonly used dietary supplements among 
breast cancer patients. EGCG may alter the metabolism of tamoxifen. Therefore, the aim of this study was to investigate the 
influence of green tea supplements on the pharmacokinetics of endoxifen; the most relevant active metabolite of tamoxifen.
Methods In this single-center, randomized cross-over trial, effects of green tea capsules on endoxifen levels were evaluated. 
Patients treated with tamoxifen for at least 3 months were eligible for this study. After inclusion, patients were consecutively 
treated with tamoxifen monotherapy for 28 days and in combination with green tea supplements (1 g twice daily; containing 
300 mg EGCG) for 14 days (or vice versa). Blood samples were collected on the last day of monotherapy or combination 
therapy. Area under the curve (AUC 0–24h), maximum concentration (Cmax) and minimum concentration (Ctrough) were obtained 
from individual plasma concentration–time curves.
Results No difference was found in geometric mean endoxifen AUC 0–24h in the period with green tea versus tamoxifen mono-
therapy (− 0.4%; 95% CI − 8.6 to 8.5%; p = 0.92). Furthermore, no differences in Cmax (− 2.8%; − 10.6 to 5.6%; p = 0.47) nor 
Ctrough (1.2%; − 7.3 to 10.5%; p = 0.77) were found. Moreover, no severe toxicity was reported during the whole study period.
Conclusions This study demonstrated the absence of a pharmacokinetic interaction between green tea supplements and 
tamoxifen. Therefore, the use of green tea by patients with tamoxifen does not have to be discouraged.
Keywords Tamoxifen · Green tea extract · Epigallocatechin-3-gallate (EGCG) · Herb–drug interaction · Pharmacokinetics · 
Toxicities · Breast cancer
Introduction
Breast cancer is the most commonly diagnosed type of can-
cer among women [1]. In the adjuvant treatment of hormone 
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and an effective oral endocrine therapy [2]. Many cancer 
patients—with estimates up to 80%—use complementary 
and alternative medicines in combination with their anti-
cancer therapy [3–7]. One of the most popular herbal supple-
ments among breast cancer patients are green tea (Camellia 
sinensis) supplements [4, 5, 8].
Green tea contains a large number of bioactive com-
pounds, such as catechins and flavonoids [9, 10]. The 
active pharmacological ingredient of green tea is epigal-
locatechin-3-gallate, EGCG [11]. EGCG is believed to 
contribute to various cancer-preventive effects resulting 
from its high antioxidant potential [11–14]. In vitro and 
animal studies reported a number of cancer-preventative 
effects of EGCG including: attenuation of oxidative stress, 
inhibition of angiogenesis, induction of apoptosis and 
alterations in expression of cell cycle regulatory proteins 
[11, 12, 14–17]. None of these effects have been proven 
clinically. However, there are also signs that green tea 
and associated substances can influence other prescribed 
drugs. For example, it has been reported that EGCG could 
significantly reduce the systemic exposure of nadolol, folic 
acid and digoxin in subjects with approximately 85%, 
39% and 31%, respectively [18–20]. Moreover, EGCG 
significantly increased the bioavailability of for exam-
ple simvastatin and verapamil in rat studies [21, 22]. The 
described interactions with these drugs are the result of 
altered bioavailability or decreased metabolism, and can 
mechanistically be explained by inhibition of influx trans-
porter organic anion transporter polypeptide (OATP) or 
efflux transporter P-glycoprotein and several phase I and 
II metabolizing enzymes (e.g., cytochrome P450 (CYP) 
3A and UDP-glucuronosyltransferase (UGT)) [18–27]. 
Simultaneous administration with green tea is therefore 
not recommended for these drugs. However, the impact of 
green tea on tamoxifen pharmacokinetics remains unclear.
Tamoxifen pharmacokinetics depends on a multi-path-
way biotransformation (Fig. 1) [28]. After hepatic uptake 
by—among others—OATP1B1, the cytochrome P450 iso-
enzymes CYP2D6 and CYP3A4 metabolize tamoxifen into 
the main metabolite endoxifen [28–31]. Endoxifen is ulti-
mately glucuronidated by UGT into an inactive metabolite 
and excreted through bile and feces [30]. In view of the 
involvement of drug transporting proteins and metaboliz-
ing enzymes, green tea could potentially interfere with 
the tamoxifen metabolism. Herb–drug interactions with 
tamoxifen could negatively impact the pharmacokinetic 
profile, as was previously shown with the combination 
of tamoxifen and curcumin [32]. Therefore, the primary 
objective of this study was to evaluate the possible phar-
macokinetic interaction between green tea supplements 
and tamoxifen. The secondary objective was to assess the 
safety profile of green tea in combination with tamoxifen.
Fig. 1  Main metabolism path-
way of tamoxifen. After absorp-
tion tamoxifen is metabolized 
mainly by CYP2D6 in its active 
metabolite endoxifen. Tamox-
ifen relies on phase II metabo-
lism before it can be excreted 
from the body. Endoxifen is 
ultimately glucuronidated into 
endoxifen-glucuronide mainly 
by UGTs. Several in vitro stud-
ies suggest inhibition by green 
tea of several phase I enzymes 
(CYP2D6 and CYP3A4) and 
inhibition of several drug-
transporters which the efflux 
transporter P-gP (ABCB1) and 
sever influx-transporters like 
OATP. P-gP P-glycoprotein, 
CYP cytochrome P450, OATP 
organic anion transporting 
polypeptide, UGT UDP-glucu-
ronosyltransferase
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Methods
Study design
This single-center, randomized, two-armed, open-label, 
pharmacokinetic cross-over trial aimed to investigate the 
endoxifen exposure in breast cancer participants using 
tamoxifen with or without green tea. The study protocol 
was written in conformity with the Declaration of Hel-
sinki and approved by the Local Medical Ethics Committee 
and registered at the Netherlands Trial Registry (Number 
NL8144). Enrollment took place after written informed con-
sent at the Erasmus University Medical Center, Rotterdam, 
The Netherlands. Patients with a confirmed histological 
or cytological diagnosis of primary breast cancer, a World 
Health Organization (WHO) performance status of ≤ 1 and 
on tamoxifen treatment at a stable dose of 20 or 40 mg q.d. 
for at least 3 months (ensuring steady-state concentration) 
were included. Participant demographics, medical history, 
CYP2D6 phenotype status and serum biochemistry were 
assessed before study entry. Participants were excluded 
if they were CYP2D6 poor or ultra-rapid metabolizers or 
if they had an impaired drug absorption. Furthermore, all 
participants were required to abstain from herbal or dietary 
supplements and strong inhibitors or inducers of CYP3A4, 
CYP2D6, UGT and P-glycoprotein. Depending on randomi-
zation, participants either started with tamoxifen monother-
apy (20 or 40 mg q.d.; 10 AM) for 28 consecutive days or 
tamoxifen and green tea (1000 mg b.i.d.; containing 150 mg 
of EGCG; 10 AM and 10 PM) concomitantly for 14 con-
secutive days. This dose of green tea capsules is equivalent 
to approximately 5 to 6 cups of regular green tea and is 
also in line with previous clinical studies. Thereafter, par-
ticipants received tamoxifen and green tea concomitantly for 
14 consecutive days or tamoxifen monotherapy for 28 days, 
respectively. The green tea capsules were manufactured by 
a qualified Dutch Pharmacy (NatuurApotheek, Pijnacker, 
the Netherlands) and the batch was provided with a certifi-
cate of analysis for verification of the EGCG content. Par-
ticipants were hospitalized for 24-h pharmacokinetic blood 
sampling on days 14 and 42, after one night of fasting. Blood 
samples were collected periodically at 13 predefined time 
points (t = 0, 0.5, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 h 
after tamoxifen intake) and after processing to plasma stored 
at − 80 °C until analysis. Plasma samples were analyzed by a 
validated liquid chromatography–tandem mass spectrometry 
(UPLC–MS/MS) method in accordance with U.S. Food and 
Drug Administration (FDA) bioanalytical method valida-
tion guidelines [33]. Adverse events were graded using the 
Common Terminology Criteria for Adverse Events version 
5.0 (CTCAEv.5, National Cancer Institute, Bethesda, MD, 
USA).
Pharmacokinetic analysis
A non-compartmental pharmacokinetic analysis of steady-
state concentrations was performed using Phoenix WinNon-
lin version 8.1 (Pharsight, a Certara Company, Princeton, 
NJ, USA). Main pharmacokinetic parameters including area 
under the curve (AUC 0–24h), maximum observed concentra-
tion (Cmax) and minimum observed concentration (Ctrough) 
were constructed by individual plasma concentration–time 
curves.
Statistical analysis
The main objective of this trial was to compare the concen-
tration of endoxifen with and without green tea supplements 
by comparing the AUC 0–24h between days 14 and 42, where 
one comparison was made: endoxifen monotherapy versus 
combined with green tea supplements. A relative difference 
in AUC 0–24h of at least 25% was considered to be clinically 
relevant and the within-patient deviation was assumed to 
be 20%. Given a power of 90% and a two-sided α of 5%, 
this resulted in a sample size of 14 evaluable patients (7 
in both treatment arms). Analyses of AUC of tamoxifen, 
and Ctrough and Cmax of both endoxifen and tamoxifen were 
performed on log-transformed observations since these are 
assumed to follow a log-normal distribution. Estimates for 
the mean differences in Ctrough and Cmax were obtained for 
one comparison (tamoxifen concomitantly with green tea 
monotherapy versus tamoxifen monotherapy) separately 
using a linear mixed effect model treatment with sequence, 
and period as fixed effects and subject within sequence as a 
random effect. Variance components were estimated based 
on restricted maximum likelihood (REML) methods, and 
the Kenward–Roger method of computing the denomina-
tor degrees of freedom was used. The antilog were taken 
from the effect estimate and corresponding 95% confidence 
interval boundaries for the comparisons of tamoxifen con-
comitantly with green tea versus tamoxifen monotherapy to 
interpret the results (interpreted as ratios of the geometric 
means).
Results
Trial participants
Between October 2019 and February 2020, a total of 14 
breast cancer patients were enrolled. All participants com-
pleted this trial and were evaluable. An overview of base-
line characteristics is presented in Table 1. Participants 
were predominantly of Caucasian origin (86%) and were 
extensive metabolizers of CYP2D6 (79%). All participants 
were treated with adjuvant tamoxifen in this trial. The vast 
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majority of patients used tamoxifen in a dose of 20 mg once 
daily (93%) and 1 patient used tamoxifen in a dose of 40 mg 
once daily (7%). In addition, the median duration of tamox-
ifen use before enrollment in this trial was 11.8 (range 6.0 
to 12.9) months.
Pharmacokinetics
Tamoxifen and endoxifen levels were detectable in all col-
lected blood samples. Estimates of main pharmacokinetic 
parameters for tamoxifen monotherapy versus tamoxifen 
with green tea supplements are presented in Table 2. The 
individual AUC values for endoxifen and tamoxifen expo-
sure without and with green tea supplements are displayed 
in Figs. 2 and 3. The geometric mean of endoxifen AUC 
0–24h during concomitant administration of green tea was 
comparable to tamoxifen monotherapy [746  nmol  h/L; 
coefficient of variation (CV): 38.6% vs 749  nmol  h/L; 
CV 41.1%]. The corresponding relative difference (RD) 
in endoxifen AUC 0–24h between the cycle with and with-
out green tea was − 0.4% (95% CI − 8.6 to 8.5%; p = 0.92). 
Endoxifen geometric means of Cmax 38.5 nmol/L; CV 37.3% 
vs 39.6 nmol/L; CV 41.7% and Ctrough 32.2 nmol/L; CV 
34.1% vs 31.9 nmol/L; CV 39.8% also did not significantly 
differ between with or without green tea.
The plasma pharmacokinetic parameters of tamoxifen 
showed a clear resemblance in AUC 0–24h with and without 
green tea (RD 4.1%, 95% CI − 6.6 to 16.1%; p = 0.44). Like-
wise, the determined relative difference of tamoxifen Cmax 
(RD − 2.2%, 95% CI − 11.8 to 8.4%; p = 0.64) and Ctrough 
(RD 6.2%, 95% CI − 6.8 to 20.9%; p = 0.34) also shared sim-
ilar results between both treatments. No differences between 
CYP2D6 phenotype groups and endoxifen exposure were 
found.
Treatment‑related adverse events
An overview of treatment-related adverse events is presented 
in Table 3. Headache, gastro-intestinal side-effects (e.g., 
constipation and dyspepsia) and polyuria were reported 
more often during the treatment with green tea vs tamoxifen 
monotherapy. A few changes in liver biochemical param-
eters (AST, ALT, GGT) occurred during administration with 
green tea, as well as a creatinine increase and platelet count 
decrease. Hot flashes were the most reported side-effects, 
but its occurrence count remained the same independent of 
green tea consumption. Adverse events were mild and seri-
ous adverse events (grade 3 or higher) were not observed 
during the study period.
Discussion
This randomized, cross-over, pharmacokinetic study clearly 
demonstrated that green tea supplements did not cause a 
pharmacokinetic interaction with tamoxifen or endoxifen 
in breast cancer patients. Therefore, we can conclude that 
tamoxifen absorption and metabolism were not affected by 
green tea from a pharmacokinetic point of view. Further-
more, serious or severe green tea related adverse events were 
not reported during the whole study period.
These results were unexpected as preclinical stud-
ies showed that green tea did modify important targets of 
tamoxifen metabolism (e.g., OATP, P-glycoprotein, UGT 
and CYP enzymes) [23, 25–27, 34]. Several mechanisms 
Table 1  Baseline characteristics of evaluable participants (N = 14)
BMI body mass index, EM extensive metabolism, IM intermedi-
ate metabolism, AST aspartate aminotransferase, ALT alanine ami-
notransferase, ALP alkaline phosphatase, GGT gamma-glutamyltrans-
ferase, LD lactate dehydrogenase, Hb hemoglobin
Characteristic N (%) or median (range)
Sex
 Female 14 (100%)
 Male 0 (0%)
Age (years) 58.5 (50.8–68.3)
BMI (kg/m2) 27.4 (23.9–28.5)
WHO performance status
 0 12 (86%)
 1 2 (14%)
Ethnic origin
 Caucasian 12 (86%)
 Afro-Caribbean 2 (14%)
CYP2D6 phenotype
 EM 11 (79%)
 IM 3 (21%)
Biochemistry
 AST (U/L) 21 (17.8–27.0)
 ALT (U/L) 15 (11.8–21.0)
 ALP (U/L) 53.5 (43–67)
 GGT (U/L) 21 (16.5–29.5)
 Total bilirubin (µmol/L) 6 (5.3–8.5)
 Albumin (g/L) 36 (35–37)
 LD (U/L) 189 (181.5–196.5)
 Hb (mmol/L) 8.1 (7.7–8.3)
 Creatinine (µmol/L) 76.5 (71.8–87.3)
Previous treatment
 Surgery 14 (100%)
 Radiotherapy 9 (64%)
 Chemotherapy 3 (21%)
Tamoxifen dose
 20 mg 13 (93%)
 40 mg 1 (7%)
Duration of adjuvant tamoxifen use 
(months)
11.8 (6.0–12.9)
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for drug interactions resulting in an altered bioavailability 
or metabolism have been reported, including inhibition of 
influx- or efflux-transporters and cytochrome P450 enzymes 
[18–22]. Furthermore, other green tea–drug combina-
tions were previously studied in humans, and significant 
herb–drug interactions with clinical implications were found 
[18, 20]. Consequently, it was hypothesized that green tea 
would induce changes in the systemic exposure of tamoxifen 
Table 2  Main pharmacokinetic 
parameters of tamoxifen and 
endoxifen
PK pharmacokinetic, CI confidence interval, AUC area under the plasma-concentration–time curve, Cmax 
maximum observed concentration, Cmin minimum observed concentration
a Values are geometric mean (% coefficient of variation)
PK parameters Tamoxifen 
 monotherapya
Tamoxifen 
with green  teaa
p-value Relative difference (%) (95% CI)
Endoxifen
 AUC 0–24h (nmol·h/L) 749 (41.1) 746 (38.6) 0.92  − 0.4 (− 8.6 to 8.5)
 Cmax (nmol/L) 39.6 (41.7) 38.5 (37.3) 0.47  − 2.8 (− 10.6 to 5.6)
 Cmin (nmol/L) 31.9 (39.8) 32.2 (34.1) 0.77 1.2 (− 7.3 to 10.5)
Tamoxifen
 AUC 0–24h (nmol·h/L) 6867 (26.1) 7150 (22.9) 0.44 4.1 (− 6.6 to 16.1)
 Cmax (nmol/L) 401.5 (28.1) 392.6 (25.1) 0.64  − 2.2 (− 11.8 to 8.4)
 Cmin (nmol/mL) 257.1 (35.6) 273.0 (24.4) 0.34 6.2 (− 6.8 to 20.9)
Fig. 2  Pharmacokinetics of endoxifen without and with concomitant 
green tea supplements
Fig. 3  Pharmacokinetics of tamoxifen without and with concomitant 
green tea supplements
Table 3  Treatment-related adverse events, graded according to 
CTCAEv.5
ASAT aspartate aminotransferase, ALAT alanine aminotransferase, 
GGT gamma-glutamyltransferase
Adverse event Tamoxifen mono-
therapy (N)
Tamoxifen with 
green tea (N)
Grade 1
 General
  Abdominal pain 2
  Headache 2 4
  Hot flashes 5 5
  Restlessness 1
 Gastro-intestinal
  Nausea 1
  Dyspepsia 1
  Gastroesophageal reflux 1
  Constipation 1
  Belching 1
  Bloating 1
 Urogenital
  Polyuria 3
  Irregular menstruation 1
  Menorrhagia 1 1
 Biochemistry
  ASAT increased 1
  ALAT increased 1
  GGT increased 1
  Creatinine increased 1
  Platelet count decreased 2
Grade ≥ 3 0 0
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and endoxifen, but no differences in endoxifen and tamox-
ifen exposure between the phase with and without green tea 
were found in this study.
The non-significant effect is not consistent with the out-
comes of a study that reported EGCG (range 3 to 10 mg/
kg) significantly altered the pharmacokinetic parameters 
of tamoxifen in rats [35]. This animal study suggested that 
EGCG might be effective to obstruct CYP3A4-mediated 
metabolism and P-glycoprotein mediated efflux pathways 
in the intestine and liver. However, a lower dose EGCG 
(0.5 mg/kg) did not significantly alter the metabolite forma-
tion of tamoxifen in rats [35]. This phenomenon suggests 
a dose-dependent effect of EGCG on the pharmacokinetic 
profile of tamoxifen. In this trial, the EGCG dose used is 
equivalent to a dose of approximately 4 mg/kg.
In this study a commercially available green tea extract 
was administered, in what is considered a high, but safe dose 
for humans (2000 mg green tea per day of which 300 mg is 
EGCG) and in line with dosages used in previous clinical 
studies and with what we observe in breast cancer patients 
in our out-patient clinic [10, 35–39]. This EGCG dose is 
equivalent to approximately about 5 to 6 cups of green tea. 
According to the European Food and Safety Association 
(European agency funded by the European Union) 300 mg 
EGCG is comparable to the maximum mean daily EGCG 
intake from the consumption of regular green tea in bever-
age form [38]. However, it is worth noting that routes of 
administration other than green tea supplements (e.g., green 
tea beverages) may in theory affect green tea absorption and 
bioavailability and therefore may affect tamoxifen pharma-
cokinetics. Therefore, it is possible that green tea beverages 
show a different bioavailability of EGCG compared with 
green tea capsules. However, a possible interaction with the 
green tea beverage is less likely since similar EGCG lev-
els are likely to be obtained in human plasma. Apparently, 
administration of green tea capsules influences the phase II 
metabolism of tamoxifen to a very limited extend.
The main reported adverse events in this trial were 
headaches, hot flashes, gastro-intestinal toxicity, polyuria 
and minor abnormalities in liver biochemical parameters. 
The incidences of headache, polyuria, gastro-intestinal 
adverse events and minor liver biochemical disturbances 
were increased in the green tea phase, whereas abdomi-
nal pain was more present without green tea. All reported 
adverse events during this study were mild (grade 1). Pre-
vious studies found similar gastro-intestinal and hepatic 
adverse events related to the administration of high doses 
of green tea [36, 37, 40]. In addition, headache, polyuria 
and restlessness are well-known side-effects of caffeine, 
one of the substituents of green tea supplements (140 mg/
day, equivalent to approximately 200 mL of filtered cof-
fee). These green tea related adverse events suggest that 
green tea was sufficiently absorbed, which is important 
because of its low oral bioavailability [13, 41, 42]. To 
ensure adequate green tea absorption, we administered 
the daily dose in two dosages and patients with known 
impaired drug absorption were excluded.
In conclusion, this study clearly indicated that tamox-
ifen and endoxifen pharmacokinetics were not affected 
by green tea supplements. Concomitant treatment with 
green tea and tamoxifen was well-tolerated in this real-
life breast cancer cohort. Therefore, the use of green tea 
among breast cancer patients does not have to be actively 
discouraged by physicians.
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